arrow
S

Stellah Mpagama

nelson mandela african institution of science & technology
H指数:28
被引数:3,035

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Transforming health systems in Tanzania towards universal health coverage: a scoping review of policy evolution, 1961-2025

坦桑尼亚卫生系统向全民健康覆盖转型:一项政策演进的范围综述,1961-2025

2026-05-280
PRE
Comparative Treatment Outcomes of Shorter Regimen in Modified All Oral Regimen with Injectable in Patients Treated for Rifampicin-resistant/Multidrug-resistant Tuberculosis in Tanzania

坦桑尼亚利福平耐药/耐多药结核病患者中,改良全口服方案中较短方案与注射剂方案的比较治疗效果

2025-10-010
PRE
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Sutezolid与bedaquiline、delamanid和moxifloxacin联合治疗肺结核(PanACEA-SUDOCU-01):一项前瞻性、开放标签、随机、Ⅱb期剂量探索试验

2025-07-080
OAAI
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

德尔帕索利德联合贝达喹啉、德拉马尼和莫西沙星治疗肺结核(PanACEA-DECODE-01):一项前瞻性、随机、开放标签、IIb期剂量探索试验

2025-07-080
OAAI
Rifampicin Exposure in Tuberculosis Patients with Comorbidities in Sub-Saharan Africa: Prioritising Populations for Treatment—A Systematic Review and Meta-analysis

撒哈拉以南非洲合并症结核病患者中利福平暴露:治疗人群的优先排序——一项系统评价和荟萃分析

2025-07-030
OA
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Bedaquiline、Delamanid和Moxifloxacin与不同剂量的Sutezolid或Delpazolid联合或单独给药治疗药物敏感型结核病的 cardiac safety

2025-07-012
OA
Developing hands-on skills on tuberculosis sponsor responsibilities and clinical trial management for END-TB in Sub-Saharan
2023-12-170
OA
Clinical standards for the management of adverse effects during treatment for TB
2023-07-0114
OAAI
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
2022-11-0318
OAAI
Clinical standards for drug-susceptible pulmonary TB
2022-07-0125
OAAI
Pharmacokinetic-Pharmacodynamic Determinants of Clinical Outcomes for Rifampin-Resistant Tuberculosis: A Multisite Prospective Cohort Study
2022-06-226
OAAI